NOVEL HETEROCYCLIC HYBRIDS AS PROMISING SCAFFOLD FOR THE MANAGEMENT OF ALZHEIMER’S DISEASE
DOI:
https://doi.org/10.22159/ijpps.2025v17i2.52596Keywords:
Alzheimer’s disease, AD, AChE inhibitor, MTDL, Neuroprotective, Neurodegenerative disorderAbstract
A large majority of instances of dementia, which is a chronic neurological disease, are directly associated with Alzheimer's Disease (AD). AD affects cognitive abilities over time and is caused by a variety of mechanisms, but still the cholinergic hypothesis is the most workable approach. This study aims to compile the most recent and interesting scaffolds/scaffold/pharmacophoric combinations to cure AD. In our search for new therapeutic leads for the treatment of AD, some nitrogen and oxygen-containing heterocyclic, including alkaloids, have been highlighted as interesting prospects. The Cholinergic Hypothesis is still the most effective and obvious treatment option for this debilitating and progressive condition and should be used for further study. The outcomes strongly suggest that the hybridization approach is also a successful strategy for identifying novel scaffolds with desirable bioactivities. This article evaluates promising therapeutic compounds and molecules that have recently been introduced as multi-target-directed agents, such as quinoline, quinoxalines, chalcones, coumarins, chromenes, piperazine, carbazoles, tacrine hybrids, donepezil hybrids, rivastigmine hybrids, galantamine hybrids etc. This includes study of workable scaffolds/scaffold/pharmacophoric combinations that may be used as future anti-Alzheimer drugs. We discuss future work that would improve our understanding of this escalating disease.
Downloads
References
Ritchie CW, Molinuevo JL, Truyen L, Satlin A, Van Der Geyten S, Lovestone S. Development of interventions for the secondary prevention of alzheimers dementia: the European prevention of alzheimers dementia (EPAD) project. Lancet Psychiatry. 2016;3(2):179-86. doi: 10.1016/S2215-0366(15)00454-X, PMID 26683239.
Wang X, Wang W, LI L, Perry G, Lee Hyoung Gon, Zhu X. Oxidative stress and mitochondrial dysfunction in alzheimers disease. Biochim Biophys Acta Mol Basis Dis. 2014;1842(8):1240-7. doi: 10.1016/J.BBADIS.2013.10.015.
Dias KS, Viegas C. Multi target-directed drugs: a modern approach for design of new drugs for the treatment of alzheimers disease. Curr Neuropharmacol. 2014;12(3):239-55. doi: 10.2174/1570159X1203140511153200, PMID 24851088.
Perez Ortiz JM, Swerdlow RH. Mitochondrial dysfunction in alzheimers disease: role in pathogenesis and novel therapeutic opportunities. Br J Pharmacol. 2019;176(18):3489-507. doi: 10.1111/BPH.14585, PMID 30675901.
Sokolov VB, Aksinenko AY, Epishina TA, Goreva TV, Grigoriev VV, Gabrelyan AV. Synthesis and biological activity of N-substituted tetrahydro-γ-Carbolins bearing bis (dimethylamino) phenothiazine moiety. Russ Chem Bull. 2015;64(3):718-22. doi: 10.1007/s11172-015-0925-3.
Makhaeva GF, Shevtsova EF, Kovaleva NV, Rudakova EV, Neganova ME, Dubova LG. Aminoadamantane conjugates with carbazole derivatives as potential multitarget agents for the treatment of alzheimers disease effect of the spacer structure. Russ Chem Bull. 2018;67(11):2121-6. doi: 10.1007/s11172-018-2338-6.
Bachurin SO, Shevtsova EF, Makhaeva GF, Grigoriev VV, Boltneva NP, Kovaleva NV. Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment. Sci Rep. 2017;7:45627. doi: 10.1038/srep45627, PMID 28358144.
Makhaeva GF, Shevtsova EF, Boltneva NP, Lushchekina SV, Kovaleva NV, Rudakova EV. Overview of novel multifunctional agents based on conjugates of γ-carbolines carbazoles tetrahydrocarbazoles phenothiazines and aminoadamantanes for treatment of alzheimers disease. Chem Biol Interact. 2019 Aug 1;308:224-34. doi: 10.1016/j.cbi.2019.05.020, PMID 31100279.
Mishra P, Kumar A, Panda G. Anti-cholinesterase hybrids as multi-target directed ligands against alzheimers disease 1998-2018. Bioorg Med Chem. 2019;27(6):895-930. doi: 10.1016/j.bmc.2019.01.025, PMID 30744931.
Rochais C, Lecoutey C, Gaven F, Giannoni P, Hamidouche K, Hedou D. Novel multi-target directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and activities as potential agents against alzheimers disease: the design of donecopride. Journal of Medicinal Chemistry. 2015 Apr 9;58(7):3172-87. doi: 10.1021/acs.jmedchem.5b00115.
Bautista Aguilera OM, Esteban G, Bolea I, Nikolic K, Agbaba D, Moraleda I. Design synthesis pharmacological evaluation QSAR analysis molecular modeling and ADMET of novel donepezil indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of alzheimers disease. Eur J Med Chem. 2014 Mar 21;75:82-95. doi: 10.1016/j.ejmech.2013.12.028, PMID 24530494.
Cai P, Fang SQ, Yang XL, WU JJ, Liu QH, Hong H. Rational design and multibiological profiling of novel donepezil trolox hybrids against alzheimers disease with cholinergic antioxidant neuroprotective and cognition-enhancing properties. ACS Chem Neurosci. 2017;8(11):2496-511. doi: 10.1021/acschemneuro.7b00257, PMID 28806057.
LI F, Wang ZM, WU JJ, Wang J, Xie SS, Lan JS. Synthesis and pharmacological evaluation of donepezil-based agents as new cholinesterase/monoamine oxidase inhibitors for the potential application against alzheimers disease. J Enzyme Inhib Med Chem. 2016 Jul;31 Suppl 3:41-53. doi: 10.1080/14756366.2016.1201814, PMID 27384289.
Golbraikh A, Bernard P, Chretien JR. Validation of protein based alignment in 3D quantitative structure-activity relationships with CoMFA models. Eur J Med Chem. 2000;35(1):123-36. doi: 10.1016/S0223-5234(00)00108-2, PMID 10733609.
Mao F, Chen J, Zhou Q, Luo Z, Huang L, LI X. Novel tacrine ebselen hybrids with improved cholinesterase inhibitory hydrogen peroxide and peroxynitrite scavenging activity. Bioorg Med Chem Lett. 2013;23(24):6737-42. doi: 10.1016/j.bmcl.2013.10.034, PMID 24220172.
Mezeiova E, Spilovska K, Nepovimova E, Gorecki L, Soukup O, Dolezal R. Profiling donepezil template into multipotent hybrids with antioxidant properties. J Enzyme Inhib Med Chem. 2018;33(1):583-606. doi: 10.1080/14756366.2018.1443326, PMID 29529892.
Mishra CB, Manral A, Kumari S, Saini V, Tiwari M. Design synthesis and evaluation of novel indandione derivatives as multifunctional agents with cholinesterase inhibition anti-β-amyloid aggregation antioxidant and neuroprotection properties against alzheimers disease. Bioorg Med Chem. 2016;24(16):3829-41. doi: 10.1016/j.bmc.2016.06.027, PMID 27353888.
Ismaili L, Refouvelet B, Benchekroun M, Brogi S, Brindisi M, Gemma S. Multitarget compounds bearing tacrine and donepezil like structural and functional motifs for the potential treatment of alzheimers disease. Prog Neurobiol. 2017 Apr;151:4-34. doi: 10.1016/j.pneurobio.2015.12.003, PMID 26797191.
Wang J, Wang ZM, LI XM, LI F, WU JJ, Kong LY. Synthesis and evaluation of multi-target directed ligands for the treatment of alzheimers disease based on the fusion of donepezil and melatonin. Bioorg Med Chem. 2016;24(18):4324-38. doi: 10.1016/j.bmc.2016.07.025, PMID 27460699.
Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with alzheimers disease. JAMA. 1994;271(13):992-8. doi: 10.1001/jama.1994.03510370044030, PMID 8139084.
Gomes AJ, Lunardi CN, Gonzalez S, Tedesco AC. The antioxidant action of Polypodium leucotomos extract and kojic acid: reactions with reactive oxygen species. Braz J Med Biol Res. 2001;34(11):1487-94. doi: 10.1590/S0100-879X2001001100018, PMID 11668361.
Galdeano C, Viayna E, Arroyo P, Bidon Chanal A, Blas JR, Munoz Torrero D. Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-alzheimer agents. Curr Pharm Des. 2010;16(25):2818-36. doi: 10.2174/138161210793176536, PMID 20698824.
Najafi Z, Mahdavi M, Saeedi M, Karimpour Razkenari E, Asatouri R, Vafadarnejad F. Novel tacrine-1,2,3-triazole hybrids: in vitro in vivo biological evaluation and docking study of cholinesterase inhibitors. Eur J Med Chem. 2017;125:1200-12. doi: 10.1016/j.ejmech.2016.11.008, PMID 27863370.
Najafi Z, Mahdavi M, Saeedi M, Karimpour Razkenari E, Edraki N, Sharifzadeh M. Novel tacrine coumarin hybrids linked to 1,2,3-triazole as anti-alzheimers compounds: in vitro and in vivo biological evaluation and docking study. Bioorg Chem. 2019;83:303-16. doi: 10.1016/j.bioorg.2018.10.056, PMID 30396115.
Jiang N, Huang Q, Liu J, Liang N, LI Q, LI Q. Design synthesis and biological evaluation of new coumarin dithiocarbamate hybrids as multifunctional agents for the treatment of alzheimers disease. Eur J Med Chem. 2018;146:287-98. doi: 10.1016/j.ejmech.2018.01.055, PMID 29407958.
Changwong N, Sabphon C, Ingkaninan K, Sawasdee P. Acetyl and butyryl cholinesterase inhibitory activities of mansorins and mansonones. Phytother Res. 2012;26(3):392-6. doi: 10.1002/ptr.3576, PMID 21780212.
Rizzo S, Bartolini M, Ceccarini L, Piazzi L, Gobbi S, Cavalli A. Targeting alzheimers disease: novel indanone hybrids bearing a pharmacophoric fragment of AP2238. Bioorg Med Chem. 2010;18(5):1749-60. doi: 10.1016/j.bmc.2010.01.071, PMID 20171894.
Anand P, Singh B, Singh N. A review on coumarins as acetylcholinesterase inhibitors for alzheimers disease. Bioorg Med Chem. 2012;20(3):1175-80. doi: 10.1016/j.bmc.2011.12.042, PMID 22257528.
Piazzi L, Cavalli A, Belluti F, Bisi A, Gobbi S, Rizzo S. Brief articles; 2007. p. 4250-4.
Alipour M, Khoobi M, Moradi A, Nadri H, Homayouni Moghadam F, Emami S. Synthesis and anti-cholinesterase activity of new 7-hydroxycoumarin derivatives. Eur J Med Chem. 2014 Jul 23;82:536-44. doi: 10.1016/j.ejmech.2014.05.056, PMID 24941128.
Catto M, Pisani L, Leonetti F, Nicolotti O, Pesce P, Stefanachi A. Design synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase. Bioorg Med Chem. 2013;21(1):146-52. doi: 10.1016/j.bmc.2012.10.045, PMID 23199476.
Kryger G, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-alzheimer drugs. Structure. 1999;7(3):297-307. doi: 10.1016/S0969-2126(99)80040-9, PMID 10368299.
Sharma P, Tripathi A, Tripathi PN, Prajapati SK, Seth A, Tripathi MK. Design and development of multitarget directed N-benzylpiperidine analogs as potential candidates for the treatment of alzheimers disease. Eur J Med Chem. 2019 Apr 1;167:510-24. doi: 10.1016/j.ejmech.2019.02.030, PMID 30784883.
Bagley MC, Bashford KE, Hesketh CL, Moody CJ. Total synthesis of the thiopeptide promothiocin A. J Am Chem Soc. 2000;122(14):3301-13. doi: 10.1021/ja994247b.
Kwong HC, Chidan Kumar CS, Mah SH, Mah YL, Chia TS, Quah CK. Crystal correlation of heterocyclic imidazo [1,2-a] pyridine analogues and their anticholinesterase potential evaluation. Sci Rep. 2019;9(1):926. doi: 10.1038/s41598-018-37486-7, PMID 30700752.
Marcade M, Bourdin J, Loiseau N, Peillon H, Rayer A, Drouin D. Etazolate a neuroprotective drug linking GABA (A) receptor pharmacology to amyloid precursor protein processing. J Neurochem. 2008;106(1):392-404. doi: 10.1111/j.1471-4159.2008.05396.x, PMID 18397369.
Umar T, Shalini S, Raza MK, Gusain S, Kumar J, Seth P. A multifunctional therapeutic approach: synthesis biological evaluation crystal structure and molecular docking of diversified 1H-pyrazolo [3, 4-b] pyridine derivatives against alzheimers disease. Eur J Med Chem. 2019 Aug 1;175:2-19. doi: 10.1016/j.ejmech.2019.04.038, PMID 31055149.
LI Y, Peng P, Tang L, HU Y, HU Y, Sheng R. Design synthesis and evaluation of rivastigmine and curcumin hybrids as site activated multitarget directed ligands for alzheimers disease therapy. Bioorg Med Chem. 2014;22(17):4717-25. doi: 10.1016/j.bmc.2014.07.009, PMID 25082512.
Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008;65(11):1631-52. doi: 10.1007/s00018-008-7452-4, PMID 18324353.
Bailey JA, Lahiri DK. A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in alzheimers disease. J Neurochem. 2010;112(4):843-53. doi: 10.1111/j.1471-4159.2009.06490.x, PMID 19912467.
Anand R, Gill KD, Mahdi AA. Therapeutics of alzheimers disease: past present and future. Neuropharmacology. 2014;76(A):27-50. doi: 10.1016/j.neuropharm.2013.07.004, PMID 23891641.
Dajas Bailador FA, Heimala K, Wonnacott S. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release. Mol Pharmacol. 2003;64(5):1217-26. doi: 10.1124/mol.64.5.1217, PMID 14573772.
Zhao LN, Chiu SW, Benoit J, Chew LY, MU Y. The effect of curcumin on the stability of Aβ dimers. J Phys Chem B. 2012;116(25):7428-35. doi: 10.1021/jp3034209, PMID 22690789.
Stavrakov G, Philipova I, Lukarski A, Atanasova M, Zheleva D, Zhivkova ZD. Galantamine curcumin hybrids as dual site binding acetylcholinesterase inhibitors. Molecules. 2020;25(15):3341. doi: 10.3390/molecules25153341, PMID 32717861.
Prasher P, Sharma M, Aljabali AA, Gupta G, Negi P, Kapoor DN. Hybrid molecules based on 1,3,5-triazine as potential therapeutics: a focused review. Drug Dev Res. 2020;81(7):837-58. doi: 10.1002/ddr.21704, PMID 32579723.
Jameel E, Meena P, Maqbool M, Kumar J, Ahmed W, Mumtazuddin S. Rational design synthesis and biological screening of triazine triazolopyrimidine hybrids as multitarget anti-alzheimer agents. Eur J Med Chem. 2017;136:36-51. doi: 10.1016/j.ejmech.2017.04.064, PMID 28478343.
Maqbool M, Manral A, Jameel E, Kumar J, Saini V, Shandilya A. Development of cyanopyridine triazine hybrids as lead multitarget anti-alzheimer agents. Bioorg Med Chem. 2016;24(12):2777-88. doi: 10.1016/j.bmc.2016.04.041, PMID 27157006.
Barea P, Barbosa VA, Alberto D, Maria C, Gomes B, Novello CR. Anticholinesterase activity of β-carboline-1,3, 5-triazine hybrids. 2022;58:e19958. doi: 10.1590/s2175-97902022e19958.
Iraji A, Firuzi O, Khoshneviszadeh M, Nadri H, Edraki N, Miri R. Synthesis and structure-activity relationship study of multi-target triazine derivatives as innovative candidates for the treatment of alzheimers disease. Bioorg Chem. 2018;77:223-35. doi: 10.1016/j.bioorg.2018.01.017, PMID 29367079.
Lozano V, Aguado L, Hoorelbeke B, Renders M, Camarasa MJ, Schols D. Targeting HIV entry through interaction with envelope glycoprotein 120 (Gp120): synthesis and antiviral evaluation of 1,3,5-triazines with aromatic amino acids. J Med Chem. 2011;54(15):5335-48. doi: 10.1021/jm200560r, PMID 21749165.
Singh UP, Bhat HR, Gahtori P. Antifungal activity SAR and physicochemical correlation of some thiazole-1,3,5-triazine derivatives. J Mycol Med. 2012;22(2):134-41. doi: 10.1016/j.mycmed.2011.12.073, PMID 23518015.
Maqbool M, Manral A, Jameel E, Kumar J, Saini V, Shandilya A. Development of cyanopyridine triazine hybrids as lead multitarget anti-alzheimer agents. Bioorg Med Chem. 2016;24(12):2777-88. doi: 10.1016/j.bmc.2016.04.041, PMID 27157006.
Vafadarnejad F, Mahdavi M, Karimpour Razkenari E, Edraki N, Sameem B, Khanavi M, Saeedi M, Akbarzadeh T. Design and synthesis of novel coumarin pyridinium hybrids: in vitro cholinesterase inhibitory activity. Bioorg Chem. 2018;77:311–9. doi: 10.1016/j.bioorg.2018.01.013.
Yazdani M, Edraki N, Badri R, Khoshneviszadeh M, Iraji A, Firuzi O. 5,6-diphenyl triazine thio methyl triazole hybrid as a new alzheimers disease-modifying agents. Mol Divers. 2020;24(3):641-54. doi: 10.1007/s11030-019-09970-3, PMID 31327094.
Saeedi M, Maleki A, Iraji A, Hariri R, Akbarzadeh T, Edraki N. Synthesis and bio-evaluation of new multifunctional methylindolinone-1,2,3-triazole hybrids as anti-alzheimers agents. J Mol Struct. 2021 Apr 5;1229. doi: 10.1016/j.molstruc.2020.129828.
Sang Z, Wang K, Shi J, Liu W, Cheng X, Zhu G. The development of advanced structural framework as multi target directed ligands for the treatment of alzheimers disease. Eur J Med Chem. 2020;192:112180. doi: 10.1016/j.ejmech.2020.112180, PMID 32131034.
Saeedi M, Safavi M, Karimpour Razkenari E, Mahdavi M, Edraki N, Moghadam FH. Synthesis of novel chromenones linked to 1,2,3-triazole ring system: investigation of biological activities against alzheimers disease. Bioorg Chem. 2017;70:86-93. doi: 10.1016/j.bioorg.2016.11.011, PMID 27914694.
Karimi Askarani H, Iraji A, Rastegari A, Abbas Bukhari SN, Firuzi O, Akbarzadeh T. Design and synthesis of multi-target directed 1,2,3-triazole-dimethylaminoacryloyl chromenone derivatives with potential use in alzheimers disease. BMC Chem. 2020;14(1):64. doi: 10.1186/s13065-020-00715-0, PMID 33134975.
Hamulakova S, Janovec L, Soukup O, Jun D, Janockova J, Hrabinova M. Tacrine coumarin and tacrine-7-chloroquinoline hybrids with thiourea linkers: cholinesterase inhibition properties kinetic study molecular docking and permeability assay for blood brain barrier. Curr Alzheimer Res. 2018;15(12):1096-105. doi: 10.2174/1567205015666180711110750, PMID 29992880.
Harel M, Schalk I, Ehret Sabatier L, Bouet F, Goeldner M, Hirth C. Quaternary ligand binding to aromatic residues in the active site gorge of acetylcholinesterase. Proc Natl Acad Sci USA. 1993;90(19):9031-5. doi: 10.1073/PNAS.90.19.9031, PMID 8415649.
Rydberg EH, Brumshtein B, Greenblatt HM, Wong DM, Shaya D, Williams LD. Complexes of alkylene linked tacrine dimers with torpedo californica acetylcholinesterase: binding of Bis5-tacrine produces a dramatic rearrangement in the active site gorge. J Med Chem. 2006;49(18):5491-500. doi: 10.1021/jm060164b, PMID 16942022.
Dawson LJ, Caulfield VL, Stanbury JB, Field AE, Christmas SE, Smith PM. Hydroxychloroquine therapy in patients with primary sjogrens syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford). 2005;44(4):449-55. doi: 10.1093/RHEUMATOLOGY/KEH506, PMID 15590764.
Katewa SD, Katyare SS. Antimalarials inhibit human erythrocyte membrane acetylcholinesterase. Drug Chem Toxicol. 2005;28(4):467-82. doi: 10.1080/01480540500262912, PMID 16298876.
Lim LY, GO ML. The anticholinesterase activity of mefloquine. Clin Exp Pharmacol Physiol. 1985;12(5):527-31. doi: 10.1111/j.1440-1681.1985.tb00904.x, PMID 3878759.
Bosak A, Opsenica DM, Sinko G, Zlatar M, Kovarik Z. Structural aspects of 4-aminoquinolines as reversible inhibitors of human acetylcholinesterase and butyrylcholinesterase. Chem Biol Interact. 2019 Mar;308:101-9. doi: 10.1016/j.cbi.2019.05.024, PMID 31100281.
Czarnecka K, Girek M, Maciejewska K, Skibinski R, Jonczyk J, Bajda M. New cyclopentaquinoline hybrids with multifunctional capacities for the treatment of alzheimers disease. J Enzyme Inhib Med Chem. 2017;33(1):158-70. doi: 10.1080/14756366.2017.1406485, PMID 29210299.
Shi DH, Min W, Song M Qiu, S XX, LI MC, Zhang Z Yuan, Liu YW, Liu WW. Synthesis characterization crystal structure and evaluation of four carbazole coumarin hybrids as multifunctional agents for the treatment of alzheimers disease. J Mol Struct. 2020 Jun 5;1209:127897. doi: 10.1016/j.molstruc.2020.127897.
Khattab SN, Haiba NS, Asal AM, Bekhit AA, Amer A, Abdel Rahman HM. Synthesis and evaluation of quinazoline amino acid derivatives as monoamine oxidase (MAO) inhibitors. Bioorg Med Chem. 2015;23(13):3574-85. doi: 10.1016/j.bmc.2015.04.021, PMID 25922182.
Bashir M, Bano A, Ijaz AS, Chaudhary BA. Recent developments and biological activities of N-substituted carbazole derivatives: a review. Molecules. 2015;20(8):13496-517. doi: 10.3390/molecules200813496, PMID 26213906.
Mongre RK, Mishra CB, Prakash A, Jung S, Lee BS, Kumari S. Novel carbazole piperazine hybrid small molecule induces apoptosis by targeting BCL-2 and inhibits tumor progression in lung adenocarcinoma in vitro and xenograft mice model. Cancers (Basel). 2019;11(9):1245. doi: 10.3390/cancers11091245, PMID 31450709.
Pedro M, Cerqueira F, Sousa ME, Nascimento MS, Pinto M. Xanthones as inhibitors of growth of human cancer cell lines and their effects on the proliferation of human lymphocytes in vitro. Bioorg Med Chem. 2002;10(12):3725-30. doi: 10.1016/S0968-0896(02)00379-6, PMID 12413829.
Zhu D, Chen M, LI M, Luo B, Zhao Y, Huang P. Discovery of novel N-substituted carbazoles as neuroprotective agents with potent anti-oxidative activity. Eur J Med Chem. 2013;68:81-8. doi: 10.1016/j.ejmech.2013.07.029, PMID 23973819.
Yoon HJ, Kong SY, Park MH, Cho Y, Kim SE, Shin JY. Aminopropyl carbazole analogues as potent enhancers of neurogenesis. Bioorg Med Chem. 2013;21(22):7165-74. doi: 10.1016/j.bmc.2013.08.066, PMID 24095011.
Brown T. Design thinking. Harv Bus Rev. 2008;86(6):84-92. doi: 10.1002/med, PMID 18605031.
Hashim NM, Rahmani M, EE GC, Sukari MA, Yahayu M, Amin MA. Antioxidant antimicrobial and tyrosinase inhibitory activities of xanthones isolated from artocarpus obtusus FM jarrett. Molecules. 2012;17(5):6071-82. doi: 10.3390/molecules17056071, PMID 22614861.
Fiesel T, Gaid M, Muller A, Bartels J, El Awaad I, Beuerle T. Molecular cloning and characterization of a xanthone prenyltransferase from hypericum calycinum cell cultures. Molecules. 2015;20(9):15616-30. doi: 10.3390/molecules200915616, PMID 26343621.
Gluszynska A. Biological potential of carbazole derivatives. Eur J Med Chem. 2015;94:405-26. doi: 10.1016/j.ejmech.2015.02.059, PMID 25794500.
Choubdar N, Golshani M, Jalili Baleh L, Nadri H, Kucukkilinc TT, Ayazgok B. New classes of carbazoles as potential multi functional anti-alzheimers agents. Bioorg Chem. 2019 Oct;91:103164. doi: 10.1016/j.bioorg.2019.103164, PMID 31398601.
Graham WV, Bonito Oliva A, Sakmar TP. Update on alzheimers disease therapy and prevention strategies. Annu Rev Med. 2017 Jan 14;68:413-30. doi: 10.1146/annurev-med-042915-103753, PMID 28099083.
Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: an important new target in alzheimers disease therapy. Int Psychogeriatr. 2002;14 Suppl 1:77-91. doi: 10.1017/S1041610203008676, PMID 12636181.
Hippius H, Neundorfer G. The discovery of alzheimers disease. Dialogues Clin Neurosci. 2003;5(1):101-8. doi: 10.31887/DCNS.2003.5.1/hhippius, PMID 22034141.
Saturnino C, Iacopetta D, Sinicropi MS, Rosano C, Caruso A, Caporale A. N-alkyl carbazole derivatives as new tools for alzheimers disease: preliminary studies. Molecules. 2014;19(7):9307-17. doi: 10.3390/molecules19079307, PMID 24991761.
Ivachtchenko AV, Golovina ES, Kadieva MG, Kysil VM, Mitkin OD, Tkachenko SE. Synthesis and SAR of 3-arylsulfonyl pyrazolo [1,5-a] pyrimidines as potent serotonin 5-HT6 receptor antagonists. Bioorg Med Chem. 2011;19(4):1482-91. doi: 10.1016/j.bmc.2010.12.055, PMID 21277782.
Ivachtchenko AV, Lavrovsky Y, Ivanenkov YA. AVN-211 novel and highly selective 5-HT6 receptor small molecule antagonist for the treatment of alzheimers disease. Mol Pharm. 2016;13(3):945-63. doi: 10.1021/acs.molpharmaceut.5b00830, PMID 26886442.
Ivachtchenko AV, Lavrovsky Y, Okun I. AVN-101: a multi-target drug candidate for the treatment of CNS disorders. J Alzheimers Dis. 2016;53(2):583-620. doi: 10.3233/JAD-151146, PMID 27232215.
Kanhed AM, Patel DV, Patel NR, Sinha A, Thakor PS, Patel KB. Indoloquinoxaline derivatives as promising multifunctional anti-alzheimer agents. J Biomol Struct Dyn. 2022;40(6):2498-515. doi: 10.1080/07391102.2020.1840441, PMID 33111617.
Singh M, Kaur M, Silakari O. Flavones: an important scaffold for medicinal chemistry. Eur J Med Chem. 2014;84:206-39. doi: 10.1016/j.ejmech.2014.07.013, PMID 25019478.
Tarek S. Mansour. 2006. 2006;5(1).
Loh ZH, Kwong HC, Lam KW, Teh SS, EE GC, Quah CK. New 3-O-substituted xanthone derivatives as promising acetylcholinesterase inhibitors. J Enzyme Inhib Med Chem. 2021;36(1):627-39. doi: 10.1080/14756366.2021.1882452, PMID 33557647.
Sokolov VB, Makhaeva GF, Aksinenko AY, Grigoriev VV, Shevtsova EF, Bachurin SO. Targeted synthesis and biological activity of polypharmacophoric agents for the treatment of neurodegenerative diseases. Russ Chem Bull. 2017;66(10):1821-31. doi: 10.1007/s11172-017-1953-y.
Negi JS, Bisht VK, Singh P, Rawat MS, Joshi GP. Naturally occurring xanthones: chemistry and biology. J Appl Chem. 2013;2013:1-9. doi: 10.1155/2013/621459.
Suwanhom P, Saetang J, Khongkow P, Nualnoi T, Tipmanee V, Lomlim L. Synthesis biological evaluation and in silico studies of new acetylcholinesterase inhibitors based on quinoxaline scaffold. Molecules. 2021;26(16):4895. doi: 10.3390/molecules26164895, PMID 34443482.
Pinto MM, Sousa ME, Nascimento MS. Xanthone derivatives: new insights in biological activities. Curr Med Chem. 2005;12(21):2517-38. doi: 10.2174/092986705774370691, PMID 16250875.
Rampa A, Montanari S, Pruccoli L, Bartolini M, Falchi F, Feoli A. Chalcone based carbamates for alzheimers disease treatment. Future Med Chem. 2017;9(8):749-64. doi: 10.4155/fmc-2017-0029, PMID 28498775.
Cruz I, Puthongking P, Cravo S, Palmeira A, Cidade H, Pinto M. Xanthone and flavone derivatives as dual agents with acetylcholinesterase inhibition and antioxidant activity as potential anti-alzheimer agents. J Chem. 2017;2017:1-16. doi: 10.1155/2017/8587260.
Zhang X, Rakesh KP, Bukhari SN, Balakrishna M, Manukumar HM, Qin HL. Multi targetable chalcone analogs to treat deadly alzheimers disease: current view and upcoming advice. Bioorg Chem. 2018 Oct;80:86-93. doi: 10.1016/j.bioorg.2018.06.009, PMID 29890362.
Duraes F, Resende DI, Palmeira A, Szemeredi N, Pinto MM, Spengler G. Xanthones active against multidrug resistance and virulence mechanisms of bacteria. Antibiotics. 2021;10(5):600. doi: 10.3390/antibiotics10050600, PMID 34069329.
Cevik UA, Osmaniye D, Saglik BN, Cavusoglu BK, Levent S, Karaduman AB. Multifunctional quinoxaline hydrazone derivatives with acetylcholinesterase and monoamine oxidases inhibitory activities as potential agents against alzheimers disease. Med Chem Res. 2020;29(6):1000-11. doi: 10.1007/s00044-020-02541-4.
Mishra CB, Gusain S, Shalini S, Kumari S, Prakash A, Kumari N. Development of novel carbazole derivatives with effective multifunctional action against alzheimers diseases: design synthesis in silico in vitro and in vivo investigation. Bioorg Chem. 2020;95:103524. doi: 10.1016/j.bioorg.2019.103524, PMID 31918396.
Son HU, Lee SH. Comparison of α-glucosidase inhibition by Cudrania tricuspidata according to harvesting time. Biomed Rep. 2013;1(4):624-8. doi: 10.3892/br.2013.111, PMID 24648998.
Souto JA, Vaz E, Lepore I, Poppler AC, Franci G, Alvarez R. Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues. J Med Chem. 2010;53(12):4654-67. doi: 10.1021/jm100244y, PMID 20491440.
Zamrodah Y. Faktor-faktor yang mempengaruhi konsumen terhadap pembelian beras organik (Studi kasus di Kecamatan Selopuro Kabupaten Blitar. 2016;15(2):1-23.
Vasilievich, A Savchuk. NF Fe, S. (12) United States Patent; 2013:4(3):62–8.
Huang W, Tang L, Shi Y, Huang S, XU L, Sheng R. Searching for the multi-target-directed ligands against alzheimers disease: discovery of quinoxaline based hybrid compounds with AChE, H₃R and BACE 1 inhibitory activities. Bioorg Med Chem. 2011;19(23):7158-67. doi: 10.1016/j.bmc.2011.09.061, PMID 22019465.
Thapa P, Upadhyay SP, Suo WZ, Singh V, Gurung P, Lee ES. Chalcone and its analogs: therapeutic and diagnostic applications in alzheimers disease. Bioorg Chem. 2021;108:104681. doi: 10.1016/j.bioorg.2021.104681, PMID 33571811.
Thiratmatrakul S, Yenjai C, Waiwut P, Vajragupta O, Reubroycharoen P, Tohda M. Synthesis biological evaluation and molecular modeling study of novel tacrine carbazole hybrids as potential multifunctional agents for the treatment of alzheimers disease. Eur J Med Chem. 2014;75:21-30. doi: 10.1016/j.ejmech.2014.01.020, PMID 24508831.
Sang Z, Wang K, Shi J, Liu W, Tan Z. Design synthesis in silico and biological evaluation of novel chalcone O carbamate derivatives as multifunctional agents for the treatment of alzheimers disease. Eur J Med Chem. 2019;178:726-39. doi: 10.1016/j.ejmech.2019.06.026, PMID 31229875.
Evranos Aksoz B, Yabanoglu Ciftci S, Ucar G, Yelekci K, Ertan R. Synthesis of some novel hydrazone and 2-pyrazoline derivatives: monoamine oxidase inhibitory activities and docking studies. Bioorg Med Chem Lett. 2014;24(15):3278-84. doi: 10.1016/j.bmcl.2014.06.015, PMID 24986657.
Xia Z, Zhang H, XU D, Lao Y, FU W, Tan H. Xanthones from the leaves of garcinia cowa induce cell cycle arrest apoptosis and autophagy in cancer cells. Molecules. 2015;20(6):11387-99. doi: 10.3390/molecules200611387, PMID 26102071.
Ruan J, Zheng C, Liu Y, QU L, YU H, Han L. Chemical and biological research on herbal medicines rich in xanthones. Molecules. 2017;22(10):1698. doi: 10.3390/molecules22101698, PMID 29019929.
Wang XQ, Zhou LY, Tan RX, Liang GP, Fang SX, LI W. Design synthesis and evaluation of chalcone derivatives as multifunctional agents against alzheimers disease. X Chem Biodivers. 2021;18(11):e2100341. doi: 10.1002/cbdv.202100341, PMID 34510699.
Wang M, Qin H L, Leng J, Ameeduzzafar, Amjad MW, Raja MA G, Hussain MA, Bukhari SN A. Synthesis and biological evaluation of new tetramethylpyrazine-based chalcone derivatives as potential anti-Alzheimer agents. Chem Biol Drug Des. 2018 Nov;92(5):1859-66. doi: 10.1111/cbdd.13355.
Published
How to Cite
Issue
Section
Copyright (c) 2025 TYAGI ALKA
This work is licensed under a Creative Commons Attribution 4.0 International License.
